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HEPATOBILIARY MALIGNANCIES
Coffee Drinking and Hepatocellular Carcinoma Risk:
A Meta-Analysis
Francesca Bravi,1 Cristina Bosetti,1 Alessandra Tavani,1 Vincenzo Bagnardi,2 Silvano Gallus,1 Eva Negri,1
Silvia Franceschi,3 and Carlo La Vecchia1,4
Severalstudiessuggestaninverserelationbetweencoffeedrinkingandriskofhepatocellular
carcinoma (HCC). We conducted a meta-analysis of published studies on HCC that in-
cluded quantitative information on coffee consumption. Ten studies were retrieved (2,260
HCC cases), including 6 case–control studies from southern Europe and Japan (1551 cases)
and 4 cohort studies from Japan (709 cases). The summary relative risk (RR) for coffee
drinkers versus non-drinkers was 0.54 (95% conﬁdence interval [CI] 0.38-0.76) for case–
control studies and 0.64 (95% CI 0.56-0.74) for cohort studies. The overall RR was 0.59
(95% CI 0.49-0.72), with signiﬁcant heterogeneity between studies. The overall summary
RR for low or moderate coffee drinkers was 0.70 (95% CI 0.57-0.85), and that for high
drinkers was 0.45 (95% CI 0.38-0.53). The summary RR for an increase of 1 cup of coffee
per day was 0.77 (95% CI 0.72-0.83) from case–control studies, 0.75 (95% CI 0.65-0.85)
from cohort studies, and 0.77 (95% CI 0.72-0.82) overall. The consistency of an inverse
relation between coffee drinking and HCC across study design and geographic areas weighs
againstamajorroleofbiasorconfounding.Coffeedrinkinghasalsobeenrelatedtoreduced
risk of other liver diseases, thus suggesting a continuum of the favorable effect of coffee on
liver function. However, subjects with liver conditions may selectively reduce their coffee
consumption. Conclusion: The present analysis provides evidence that the inverse relation
between coffee and HCC is real, though inference on causality remains open to discussion.
(HEPATOLOGY 2007;46:430-435.)
S
everal data have been reported on a potentially fa-
vorable effect of coffee on liver function and liver
diseases, including liver enzymes, cirrhosis, and
hepatocellular carcinoma (HCC).1
Coffee consumption has been inversely related to
-glutamyltransferase and aminotransferase activity in
studies from Europe, Japan, and the United States.1-4
Such inverse relations are stronger in high-risk subjects,
particularly in heavy drinkers.1,5-10 Coffee drinking has
alsobeeninverselyrelatedtotheriskofcirrhosis—amajor
correlate of HCC11-13—in studies from North America
and Europe.14-18
At least 11 studies conducted in southern Europe and
Japan have considered the relation between coffee drink-
ing and the risk of HCC. A Greek case–control study of
333 cases reported an age-adjusted and sex-adjusted odds
ratio (OR) of 0.7 for drinkers of 20 cups of coffee per
week compared with those who never drink coffee.12 An
Italian case–control study of 151 cases of HCC reported
a multivariate OR of 0.78 for drinkers of 3 cups of
coffee per day compared with occasional drinkers.19 An
updateanalysisoftheItalianstudy,20including501HCC
cases, reported an OR of 0.5 for drinkers of 3 cups per
day compared with never drinkers, with a signiﬁcant
trend in risk with dose. The combined analysis of the
Greek and Italian case–control studies20 gave an OR of
0.7 for drinkers of 3 cups per day compared with never
drinkers, with a signiﬁcant trend in risk. The inverse re-
lation was also evident among subjects with a history of
infection with HBV and/or HCV. In another Italian
case–control study of 250 cases, OR was 0.8 for drinkers
of 1-2 cups per day, 0.4 for drinkers of 3-4 cups per day,
Abbreviations: HCC, hepatocellular carcinoma; OR, odds ratio; RR, relative
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430and 0.3 for drinkers of 5 cups per day.21 In an addi-
tional Italian case–control study of 185 HCC cases, OR
was 0.4 for drinkers of 3 cups per day compared with
never drinkers, with a signiﬁcant trend in risk.22 The in-
verse relation was also observed among heavy alcohol
drinkers and in subjects with or without serological evi-
dence of hepatitis.22 A Japanese case–control study of 73
cases of HCC assessed the role of coffee consumption on
the risk of HCC among cases and controls with serologi-
cal evidence of HCV.23 Regular coffee drinkers (1 cup
per day) had an OR of 0.38 compared with nondrinkers.
Another Japanese case–control study included 209 cases
of HCC and 3 different groups of controls (1,253 com-
munity controls, 275 hospital controls, 381 chronic liver
diseases patients without HCC).24 For coffee consump-
tion 10 years before diagnosis, adjusted ORs for occa-
sional use, 1-2 cups per day, and 3 cups per day
comparedwithnousewere0.33,0.27,0.22,respectively,
using community controls. Corresponding ORs were
0.86, 0.62, and 0.53 in chronic liver disease patients. In a
case–control study conducted in Haimen, China, only 7
cases and 7 controls reported to drink coffee at least twice
per month, with a corresponding OR of 1.08.25
A Japanese prospective study of 90,452 subjects fol-
lowed for 10 years and including 334 HCC cases found
that drinkers of 5 cups of coffee per day had a lower
HCC risk (relative risk [RR]  0.24) than those who
almost never consumed coffee, with a signiﬁcant trend in
risk.26 A pooled analysis of 2 other Japanese cohort stud-
ies, including 22,404 and 38,703 subjects followed for 9
and 6 years, respectively, and a total of 117 HCC cases,
yielded a RR of 0.58 for drinkers of 1 cup per day
compared with never drinkers.27 The beneﬁcial effect of
coffee was also evident among subjects with a history of
HBV or HCV. In another cohort investigation from Ja-
pan (the Japan Collaborative Cohort Study for Evalua-
tion of Cancer Risk [JACC] Study),28 including 83,966
subjects followed for up to 11 years, and 258 cases, the
multivariate RR was 0.50 for regular (1 cup per day)
coffee drinkers. The inverse relation was similar in men
and women, and in subjects with and without history of
liver disease.
We have combined all published data on this issue to
obtain an overall quantitative estimate of the association
between coffee drinking and HCC.
Materials and Methods
Search Strategy and Selection Criteria. We per-
formedaMEDLINEsearchoftheliteraturefrom1966to
February 2007 using the MeSH terms “coffee” and com-
binations of “hepatocellular” or “liver” and “carcinoma”
or “neoplasm.” Additionally, the reference lists of the
identiﬁedpublicationswerecross-checkedtoobtainother
pertinent publications. We considered articles presenting
data from case–control and cohort studies that were orig-
inally published in English. We identiﬁed 11 papers: 8
case–control studies12,19-25 and 3 cohort studies26-28 (Ta-
ble 1). Among these, Gallus et al.20 reported data from 2
case–control studies conducted in Greece12 and Italy19
that we considered separately. Similarly, Shimazu et al.27
presenteddatafrom2prospectivecohortsthatweconsid-
eredas2differentstudies(cohort1andcohort2).Wedid
not include in the meta-analysis a case–control study
from China25 that did not report daily or weekly coffee
consumption. When the data of a study were included in
more than 1 publication, only the most recent and com-
plete study was included in the meta-analysis.
For each study, we extracted details on study design,
number of subjects (cases and controls or person-years),
daily or weekly consumption of coffee, and control of
confounding factors. We did not assign quality scores to
studies,andnostudieswereexcludedaprioriforweakness
of design or data quality.
Statistical Methods. The measure of interest was the
RR for cohort studies, approximated by the OR in case–
control studies, and the corresponding 95% CI. When
RRs were not available in the published article, they were
computed from the exposure distributions. Because the
variousstudiesuseddifferentunitstomeasurecoffeecon-
sumption, we converted these into cups per day as a stan-
dardmeasure.Publicationbiaswasevaluatedusingfunnel
plots29 and Egger’s test.30
To compute summary RR for various levels of coffee
consumption, we ﬁrst calculated the study-speciﬁc esti-
mates separately for low or moderate consumption (de-
ﬁnedas3cupsperdayforGallusetal.,20Gelattietal.,21
Inoueetal.,26andMontellaetal.,22andas1cupperday
forKurozawaetal.,28Shimazuetal.,27Ohfujietal.,23and
Tanaka et al.24) and high consumption (deﬁned as 3
cups per day for Gallus et al.,20 Gelatti et al.,21 Inoue et
al.,26 and Montella et al.22 and as 1 cup per day for
Kurozawa et al.,28 Shimazu et al.,27 Ohfuji et al.,23 and
Tanaka et al.24).
We computed the summary RR for coffee drinkers
versus non-drinkers and for different levels of consump-
tion by giving each study-speciﬁc RR a weight propor-
tional to its precision (i.e., the inverse of the variance,
derived, when necessary, from the reported 95% CI).31
We calculated summary estimates for the 2 study types
(case–control and cohort) separately, as well as in combi-
nation. We assessed the statistical heterogeneity among
studies using the 2 test; results were deﬁned as heteroge-
neous for P values less than 0.10.31 We pooled the study-
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random effect model proposed by DerSimonian and
Laird32 when a signiﬁcant heterogeneity was found.
Because some studies provided risk estimates for sub-
jects with a history of hepatitis or liver disease20,27,28 or
serological evidence of HBV and/or HCV,22,23 we also
computed the summary RR for coffee drinkers versus
non-drinkers in those subjects.
For dose–response analysis, we used the method pro-
posed by Greenland and Longnecker33 to estimate study-
speciﬁcslopesfromthenaturallogarithmoftheRRacross
exposure categories, assigning to each class the dose cor-
responding to the midpoint of the range. Because the
higher category of consumption was usually open, we
considered it of the same amplitude as the preceding cat-
egory. Then, we obtained the summary RR estimates by
pooling the study-speciﬁc slopes, using the inverse of the
corresponding variances as weights.
Forest plots were given. In these graphs, a square was
plotted for each study whose center projection on the
underlying scale corresponded to the study-speciﬁc RR.
The area of the square was proportional to the inverse of
the variance of the natural logarithm of the RR and thus
gives a measure of the amount of statistical information
available from that particular estimate. A diamond was
used to plot the summary RRs, the center of which rep-
resents the RR; the extremes of the summary RRs show
the 95% CIs.
Results
Figure 1 and Table 2 show the RR for coffee drinkers
versusneverdrinkersincase–controlstudies,cohortstud-
ies, and overall. The combined summary RR from all
studies was 0.59 (95% CI 0.49-0.72). The summary RR
from case–control studies was 0.54 (95% CI 0.38-0.76).
The summary RR from cohort studies was 0.64 (95% CI
Table 1. Case–Control and Cohort Studies on Coffee Consumption and HCC
Study Country
No. of
Cases
No. of
Controls/Size
of Cohort
Duration
of
Follow-up Adjustment
Case-control studies
Kuper et al.12,20,* Greece 333 360 — Age, sex
Gallus et al.20,* Italy 501 1,552 — Age, sex
Gelatti et al.21,* Italy 250 500 — Age, sex, alcohol drinking, HCV, HBV
Montella et al.22,*† Italy 185 412 — Age, sex, education, tobacco smoking, alcohol consumption,
serological evidence of HCV and/or HBV infection
Ohfuji et al.23 Japan 73 253 — Duration of liver disease, body mass index, disease severity,
family history of liver disease, interferon therapy, tobacco
smoking, alcohol consumption, consumption of other
caffeine-containing beverages
Tanaka et al.24,‡ Japan 209 1,253 — Age, sex, alcohol consumption, tobacco smoking
Cohort studies
Inoue et al.26 Japan 334 90,452 10 years Age, sex, study center, tobacco smoking, alcohol
consumption, vegetable consumption, tea consumption
Shimazu et al.27 (cohort 1) Japan 70 22,404 9 years Age, sex, history of liver disease, tobacco smoking, alcohol
consumption
Shimazu et al.27 (cohort 2) Japan 47 38,703 6 years Age, sex, history of liver disease, tobacco smoking, alcohol
consumption
Kurozawa et al.28 Japan 258 83,966 11 years Age, sex, education, history of diabetes and liver disease,
tobacco smoking, alcohol consumption
*Hospital-based case-control study.
†OR computed from published frequencies.
‡Population-based case-control study.
Fig. 1. Summary RRs of HCC for coffee drinkers versus non-drinkers
from case–control and cohort studies.
432 BRAVI ET AL. HEPATOLOGY, August 20070.56-0.74). Signiﬁcant heterogeneity was found between
studies (pimarily case–control), and borderline signiﬁ-
cant heterogeneity was found between case–control and
cohort study estimates (2  3.49; P  0.06).
Figure 2 and Table 2 show the RRs for each case–
control study and cohort study separately and overall ac-
cording to low or moderate and high level of coffee
consumption. The summary RR for moderate consump-
tion of coffee was 0.70 (95% CI 0.57-0.85), wherein the
RRwas0.68(95%CI0.48-0.96)forcase–controlstudies
and 0.70 (95% CI 0.60-0.82) for cohort studies. The
summary RR for high consumption of coffee was 0.45
Table 2. Summary RRs and Corresponding 95% CI for Coffee Consumption and HCC
No. of
Cases RR (95% CI)
2,d f( P Value)
for Heterogeneity
Drinkers versus non-drinkers
All studies 2,260 0.59 (0.49–0.72) 29.56, 9 (0.001)
Case–control studies 1,551 0.54 (0.38–0.76) 24.22, 5 (0.001)
Cohort studies 709 0.64 (0.56–0.74) 1.85, 3 (0.60)
Low or moderate* drinkers versus non-drinkers
All studies 2,260 0.70 (0.57–0.85) 20.71, 9 (0.01)
Case-control studies 1,551 0.68 (0.48–0.96) 18.00, 5 (0.003)
Cohort studies 709 0.70 (0.60–0.82) 2.69, 3 (0.44)
High† drinkers versus non-drinkers
All studies 2,260 0.45 (0.38–0.53) 11.07, 9 (0.27)
Case-control studies 1,551 0.42 (0.32–0.55) 9.12, 5 (0.10)
Cohort studies 709 0.50 (0.38–0.66) 1.07, 3 (0.78)
Increment of 1 cup per day
All studies 2,260 0.77 (0.72–0.82) 10.45, 9 (0.16)
Case–control studies 1,551 0.77 (0.72–0.83) 8.45, 5 (0.13)
Cohort studies 709 0.75 (0.65–0.85) 1.73, 3 (0.63)
*Low or moderate consumption was deﬁned as 3 cups per day for Gallus et al.,20 Gelatti et al.,21 Inoue et al.,26 and Montella et al.22 and as 1 cup per day
for Ohfuji et al.,23 Tanaka et al.,24 Kurozawa et al.,28 and Shimazu et al.27
†High consumption was deﬁned as 3 cups per day for Gallus et al.,20 Gelatti et al.,21 Inoue et al.,26 and Montella et al.22 and as 1 cup per day for Ohfuji et
al.,23 Tanaka et al.,24 Kurozawa et al.,28 and Shimazu et al.27
Fig. 2. Summary RRs of HCC for low or moderate and high coffee drinkers versus non-drinkers from case–control and cohort studies. (A) Low or
moderate consumption was deﬁned as 3 cups per day for Gallus et al.,20 Gelatti et al.,21 Inoue et al.,26 and Montella et al.22 and as 1 cup
per day for Ohfuji et al.,23 Tanaka et al.,24 Kurozawa et al.,28 and Shimazu et al.27 (B) High consumption was deﬁned as 3 cups per day for Gallus
et al.,20 Gelatti et al.,21 Inoue et al.,26 and Montella et al.22 and as 1 cup per day for Ohfuji et al.,23 Tanaka et al.,24 Kurozawa et al.,28 and Shimazu
et al.27
HEPATOLOGY, Vol. 46, No. 2, 2007 BRAVI ET AL. 433(95% CI 0.38-0.53), wherein the RR was 0.42 (95% CI
0.32-0.55) for case–control studies and 0.50 (95% CI
0.38-0.66) for cohort studies. No signiﬁcant heterogene-
ity was found between studies or study types for high and
low coffee consumption.
Table 2 also gives the summary RRs for an increment
of 1 cup per day of coffee. These were 0.77 (95% CI
0.72-0.82) for all studies combined, 0.77 (95% CI 0.72-
0.83) for case–control studies, and 0.75 (95% CI 0.65-
0.85) for cohort studies.
Figure3givesRRforcoffeedrinkersversusnon-drink-
ers among subjects with clinical history or serological ev-
idenceofhepatitis.ThesummaryRRswere0.56(95%CI
0.40-0.77) for those reporting information on history of
hepatitis, 0.49 (95% CI 0.31-0.77) for those with sero-
logical evidence of hepatitis, and 0.53 (95% CI 0.41-
0.69) overall.
Discussion
In the present meta-analysis, we observed a 41% reduc-
tion in the risk of HCC among coffee drinkers compared
with never drinkers, with similar results from case–control
and prospective studies. Moreover, the apparent favorable
effect of coffee drinking was found both in studies from
southern Europe,12,19-22 where coffee is widely consumed,
and from Japan,23,24,26-28 where coffee consumption is less
frequent, and in subjects with chronic liver disease.
Animal models and cell culture systems have indicated
that some coffee compounds—including diterpenes, caf-
estol, and kahweol—may act as blocking agents via mod-
ulation of multiple enzymes involved in carcinogenic
detoxiﬁcation.34,35 They also modify the xenotoxic me-
tabolism via induction of glutathione-S-transferase and
inhibition of N-acetyltransferase.36 Other components of
coffee, including caffeine and antioxidant substances
from coffee beans, have been related to favorable modiﬁ-
cationsinliverenzymessuchas-glutamyltransferaseand
aminotransferase activities.1-4
Coffee has also been related to reduced risk of liver
disease and cirrhosis,14-18,37 a major risk factor or patho-
genic step in the process of liver carcinogenesis.11-13 The
beneﬁcial effect of coffee consumption on HCC may be
due to its inverse relation with cirrhosis, although allow-
anceforclinicalhistoryofcirrhosisdidnottotallyaccount
for the inverse association. Thus, there seems to be a con-
tinuum of the favorable effect of coffee on liver enzymes,
cirrhosis, and HCC.
Despite the consistency of these results, it is difﬁcult to
determine causality on the basis of these observational stud-
ies alone. The inverse relation observed may in fact be spu-
riousandduetothefactthatsubjectswithabroadspectrum
of digestive tract diseases, liver disorders, and cirrhosis may
reduce their coffee consumption. The observation that high
coffee drinkers in various populations (ie, subjects drinking
3 cups per day in Europe, but only 1 in Japan) have
similar reduced risks may support this selective reduction of
coffee drinking by subjects with digestive tract complaints.
Avoidanceofcoffeeis,however,notroutinelyrecommended
to patients with chronic liver disease, and an inverse relation
was observed among subjects with self-reported or serologi-
cal evidence of hepatitis. Moreover, in a study that also used
patients with chronic liver disease as controls,24 a similar
reduced risk was found.
Observational studies included in this meta-analysis are
prone to various other sources of bias and confounding. An
importantproblemconcernstheassessmentofcoffeeintake,
based on patients’ self-reporting. However, recall of coffee
drinking has been shown satisfactorily reproducible and val-
id.38,39Theobservationofaninverserelationbetweencoffee
and HCC in case-control and cohort studies, and in popu-
lations from southern Europe and Japan weighs against a
major role of information or selection bias in these studies.
Allowanceforconfoundingfactorsvariedamongthestudies
considered in this meta-analysis. However, the fact that the
inverse relation persisted after allowance for major risk fac-
tors for HCC, including history or serological evidence of
hepatitis B and C, cirrhosis and other liver diseases, social
class indicators, alcohol drinking and tobacco smoking, re-
assures against major role of confounding or modifying ef-
fect.Publicationbiasisalsopossible,withselectivereporting
of favorable ﬁndings. We did not search for unpublished
data or abstracts, given the difﬁculties in their interpreta-
tions.However,nosigniﬁcantasymmetrywaspresentinthe
Fig. 3. Summary RRs of HCC for coffee drinkers versus non-drinkers
among carriers of HBV and/or HCV or other chronic liver diseases.
434 BRAVI ET AL. HEPATOLOGY, August 2007funnel plot, an additional indicator of the validity of the
results.
In conclusion, the results of this meta-analysis provide
quantitative evidence of an inverse relation between cof-
fee drinking and liver cancer, the third-most common
cause of cancer death worldwide after lung and stomach,
with about 600,000 deaths in 2002.40 However, the in-
terpretation of this association remains unclear, and the
consequent inference of causality and worldwide public
health implications remains open to discussion.
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